ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 172

Serum Chemokines and miRNA Levels and Its Association with Cumulative Organ Damage in Patients with Antiphospholipid Syndrome: A Bench to Bedside Study

Laura-Aline Martinez-Martinez1, Fausto Sanchez-Muñoz2, Maya Jazmin Nastia Nicte Chacon-Perez2, Yaneli Juarez-Vicuña2, Nicole Mouneu Ornelas1, Anthony Beltran-Cortez2, Ricardo Alberto Venegas Yañez3, Julio Fonseca Basurto1, Evelyn Aranda Cano1, Mary Carmen Amigo4 and Luis M. Amezcua-Guerra1, 1Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, 2Immunology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, 3Reumatologia, Instituto Nacional de Cardiología "Ignacio Chavez", Ciudad de México, Mexico, 4Rheumatology, Centro Medico ABC, Mexico, Mexico

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: antiphospholipid syndrome, chemokines and thrombosis, MicroRNA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Antiphospholipid Syndrome Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Recent evidence suggests that chemokines and miRNAs are involved in the pathogenesis of antiphospholipid syndrome (APS). However, the specific role of these molecules in both cumulative thrombotic damage and in risk of thrombosis is still not well understood. The aim of this study was to explore the association between autoimmunity related chemokines and miRNAs with cumulative organ damage as well as the clinical risk of thrombosis in patients with APS.

Methods: This cross-sectional study included patients with APS Sapporo/Sydney criteria from a single outpatient rheumatology clinic. Demographic, clinical and clinimetric data (DIAPS, Damage Index in patients with Thrombotic Antiphospholipid Syndrome; aGAPSS, adjusted Global Anti-Phospholipid Syndrome Score and SLEDAI, Systemic Lupus Erythematosus Disease Activity Index) were recorded. Serum samples were obtained in the same visit and levels of chemokines BLC (B lymphocyte chemoattractant), IP10 (IFN-γ-induced protein 10), MCP-1 (monocyte chemoattractant protein-1) and MIG (monokine-induced-by-IFN-γ) were measured by multiplex bead array technology (Luminex MAGPIX System). In addition, relative expression of miR-19, miR-20, miR-126, and miR-155 was measured by qtPCR. Sera from healthy individuals were evaluated for reference. Normality analysis was performed with Kolmogorov-Smirnov test and comparisons were made with Mann-Whitney U test. Associations were evaluated with exact Fisher’s test and Spearman rho coefficient. ROCs were used to investigate miRNAs cut-off points. IBM SPSS version 23.0 was used for calculations.

Results: Sixty five APS patients were included, mean age was 43±14 years old, 73% were female and 53% primary APS. DIAPS correlates with number of thrombosis (0.381, p=0.003), anti-cardiolipin antibodies IgG (0.328, p=0.030), anti-β2GPI IgG (0.366, p=0.017) and BLC (0.385, p=0.015). Anti-cardiolipin IgG (0.395, p=0.010) and BCL (0.359, p=0.025) also correlates with aGAPSS. SLEDAI correlates with miR-126 (0.637, p=0.001) in secondary APS. The tissue factor related miRNAs, miR-19 (AUC=0.812, p<0.0001) and miR-20 (0.834 p< 0.0001) were able to differentiate patients from controls. Interestingly, miR-20 ≤ 0.0198 was associate to the presence of anticardiolipin (p=0.048) and a tendency of triple positivity (p=0.093) as well as recurrent thrombosis (p=0.075).

Conclusion: Our results suggest that BLC, miRNA-19 and miRNA-20 may be involved in the accrural damage in APS and risk of thrombosis. Wide and prospective studies to explore processes related to accumulation of chronic damage in APS are needed. The long time follow up for clinical end-points is the challenge for validating new potential circulating biological markers.


Disclosure: L. A. Martinez-Martinez, None; F. Sanchez-Muñoz, None; M. J. N. N. Chacon-Perez, None; Y. Juarez-Vicuña, None; N. M. Ornelas, None; A. Beltran-Cortez, None; R. A. Venegas Yañez, None; J. Fonseca Basurto, None; E. Aranda Cano, None; M. C. Amigo, None; L. M. Amezcua-Guerra, None.

To cite this abstract in AMA style:

Martinez-Martinez LA, Sanchez-Muñoz F, Chacon-Perez MJNN, Juarez-Vicuña Y, Ornelas NM, Beltran-Cortez A, Venegas Yañez RA, Fonseca Basurto J, Aranda Cano E, Amigo MC, Amezcua-Guerra LM. Serum Chemokines and miRNA Levels and Its Association with Cumulative Organ Damage in Patients with Antiphospholipid Syndrome: A Bench to Bedside Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/serum-chemokines-and-mirna-levels-and-its-association-with-cumulative-organ-damage-in-patients-with-antiphospholipid-syndrome-a-bench-to-bedside-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-chemokines-and-mirna-levels-and-its-association-with-cumulative-organ-damage-in-patients-with-antiphospholipid-syndrome-a-bench-to-bedside-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology